DOCSLIB.ORG

NDC Codes of Prescription Drugs Used As Covariates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NDC Codes of Prescription Drugs Used As Covariates CHC-CVD final report 110715 Appendix D - NDC Codes of Prescription Drugs Used as Covariates drug_class DRUG_GROUP GENERIC_NM NDC 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00078036405 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00078037905 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00078038405 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00078040405 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00078040505 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00078040605 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00083225530 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00083226030 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00083226530 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00093737001 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00093737101 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00093737201 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00093737301 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00781227101 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00781227201 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00781227210 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00781227301 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00781227310 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 00781227401 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 55111033901 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 55111034001 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 55111034101 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 68180075501 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 68180075601 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 68180075701 1 ACE_INHIBITORS AMLODIPINE BESY-BENAZEPRIL HCL 68180075801 1 ACE_INHIBITORS BENAZEPRIL HCL 00078044705 1 ACE_INHIBITORS BENAZEPRIL HCL 00078044805 1 ACE_INHIBITORS BENAZEPRIL HCL 00078044905 1 ACE_INHIBITORS BENAZEPRIL HCL 00078045005 1 ACE_INHIBITORS BENAZEPRIL HCL 00083005930 1 ACE_INHIBITORS BENAZEPRIL HCL 00083005990 1 ACE_INHIBITORS BENAZEPRIL HCL 00083006330 1 ACE_INHIBITORS BENAZEPRIL HCL 00083006390 Appendix D 1 CHC-CVD final report 110715 drug_class DRUG_GROUP GENERIC_NM NDC 1 ACE_INHIBITORS BENAZEPRIL HCL 00083007930 1 ACE_INHIBITORS BENAZEPRIL HCL 00083007932 1 ACE_INHIBITORS BENAZEPRIL HCL 00083007990 1 ACE_INHIBITORS BENAZEPRIL HCL 00083009430 1 ACE_INHIBITORS BENAZEPRIL HCL 00083009432 1 ACE_INHIBITORS BENAZEPRIL HCL 00093512401 1 ACE_INHIBITORS BENAZEPRIL HCL 00093512501 1 ACE_INHIBITORS BENAZEPRIL HCL 00093512505 1 ACE_INHIBITORS BENAZEPRIL HCL 00093512601 1 ACE_INHIBITORS BENAZEPRIL HCL 00093512605 1 ACE_INHIBITORS BENAZEPRIL HCL 00093512701 1 ACE_INHIBITORS BENAZEPRIL HCL 00172535060 1 ACE_INHIBITORS BENAZEPRIL HCL 00172535160 1 ACE_INHIBITORS BENAZEPRIL HCL 00172535260 1 ACE_INHIBITORS BENAZEPRIL HCL 00172535270 1 ACE_INHIBITORS BENAZEPRIL HCL 00172535360 1 ACE_INHIBITORS BENAZEPRIL HCL 00185004801 1 ACE_INHIBITORS BENAZEPRIL HCL 00185004805 1 ACE_INHIBITORS BENAZEPRIL HCL 00185005301 1 ACE_INHIBITORS BENAZEPRIL HCL 00185005305 1 ACE_INHIBITORS BENAZEPRIL HCL 00185050501 1 ACE_INHIBITORS BENAZEPRIL HCL 00185082001 1 ACE_INHIBITORS BENAZEPRIL HCL 00185082005 1 ACE_INHIBITORS BENAZEPRIL HCL 00378044101 1 ACE_INHIBITORS BENAZEPRIL HCL 00378044301 1 ACE_INHIBITORS BENAZEPRIL HCL 00378044401 1 ACE_INHIBITORS BENAZEPRIL HCL 00378044701 1 ACE_INHIBITORS BENAZEPRIL HCL 00781189101 1 ACE_INHIBITORS BENAZEPRIL HCL 00781189201 1 ACE_INHIBITORS BENAZEPRIL HCL 00781189301 1 ACE_INHIBITORS BENAZEPRIL HCL 00781189401 1 ACE_INHIBITORS BENAZEPRIL HCL 51079014520 1 ACE_INHIBITORS BENAZEPRIL HCL 51079014620 1 ACE_INHIBITORS BENAZEPRIL HCL 54458095610 1 ACE_INHIBITORS BENAZEPRIL HCL 54458095710 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034104 Appendix D 2 CHC-CVD final report 110715 drug_class DRUG_GROUP GENERIC_NM NDC 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034204 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034208 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034304 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034308 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034404 1 ACE_INHIBITORS BENAZEPRIL HCL 58177034408 1 ACE_INHIBITORS BENAZEPRIL HCL 60505026501 1 ACE_INHIBITORS BENAZEPRIL HCL 60505026601 1 ACE_INHIBITORS BENAZEPRIL HCL 60505026701 1 ACE_INHIBITORS BENAZEPRIL HCL 60505026705 1 ACE_INHIBITORS BENAZEPRIL HCL 60505026801 1 ACE_INHIBITORS BENAZEPRIL HCL 62037051701 1 ACE_INHIBITORS BENAZEPRIL HCL 62037051801 1 ACE_INHIBITORS BENAZEPRIL HCL 62037051901 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073601 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073605 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073690 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073701 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073705 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073790 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073801 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073805 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073890 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073901 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073905 1 ACE_INHIBITORS BENAZEPRIL HCL 63304073990 1 ACE_INHIBITORS BENAZEPRIL HCL 65162075110 1 ACE_INHIBITORS BENAZEPRIL HCL 65162075210 1 ACE_INHIBITORS BENAZEPRIL HCL 65162075310 1 ACE_INHIBITORS BENAZEPRIL HCL 65162075410 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00078045105 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00078045205 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00078045305 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00078045405 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00083005730 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00083007230 Appendix D 3 CHC-CVD final report 110715 drug_class DRUG_GROUP GENERIC_NM NDC 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00083007430 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00083007530 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00172536060 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00172536160 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00172536260 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00172536270 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00172536360 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00172536370 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00185012401 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00185020401 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00185021101 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00185027701 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00378472501 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00378473501 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00378474501 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00378477501 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00781513201 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00781513301 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 00781513401 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 62037075701 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 62037075801 1 ACE_INHIBITORS BENAZEPRIL-HYDROCHLOROTHIAZIDE 62037075901 1 ACE_INHIBITORS CAPTOPRIL 00000000223 1 ACE_INHIBITORS CAPTOPRIL 00000001043 1 ACE_INHIBITORS CAPTOPRIL 00003045051 1 ACE_INHIBITORS CAPTOPRIL 00003045054 1 ACE_INHIBITORS CAPTOPRIL 00003045075 1 ACE_INHIBITORS CAPTOPRIL 00003045250 1 ACE_INHIBITORS CAPTOPRIL 00003045251 1 ACE_INHIBITORS CAPTOPRIL 00003045275 1 ACE_INHIBITORS CAPTOPRIL 00003048250 1 ACE_INHIBITORS CAPTOPRIL 00003048251 1 ACE_INHIBITORS CAPTOPRIL 00003048275 1 ACE_INHIBITORS CAPTOPRIL 00003048550 1 ACE_INHIBITORS CAPTOPRIL 00047055924 1 ACE_INHIBITORS CAPTOPRIL 00093009101 Appendix D 4 CHC-CVD final report 110715 drug_class DRUG_GROUP GENERIC_NM NDC 1 ACE_INHIBITORS CAPTOPRIL 00093009110 1 ACE_INHIBITORS CAPTOPRIL 00093009201 1 ACE_INHIBITORS CAPTOPRIL 00093009210 1 ACE_INHIBITORS CAPTOPRIL 00093009701 1 ACE_INHIBITORS CAPTOPRIL 00093009710 1 ACE_INHIBITORS CAPTOPRIL 00093009801 1 ACE_INHIBITORS CAPTOPRIL 00093813201 1 ACE_INHIBITORS CAPTOPRIL 00093813210 1 ACE_INHIBITORS CAPTOPRIL 00093813301 1 ACE_INHIBITORS CAPTOPRIL 00093813310 1 ACE_INHIBITORS CAPTOPRIL 00093813401 1 ACE_INHIBITORS CAPTOPRIL 00093813410 1 ACE_INHIBITORS CAPTOPRIL 00093813501 1 ACE_INHIBITORS CAPTOPRIL 00143117101 1 ACE_INHIBITORS CAPTOPRIL 00143117110 1 ACE_INHIBITORS CAPTOPRIL 00143117201 1 ACE_INHIBITORS CAPTOPRIL 00143117210 1 ACE_INHIBITORS CAPTOPRIL 00143117301 1 ACE_INHIBITORS CAPTOPRIL 00143117310 1 ACE_INHIBITORS CAPTOPRIL 00143117401 1 ACE_INHIBITORS CAPTOPRIL 00179121401 1 ACE_INHIBITORS CAPTOPRIL 00179121501 1 ACE_INHIBITORS CAPTOPRIL 00185003101 1 ACE_INHIBITORS CAPTOPRIL 00185006101 1 ACE_INHIBITORS CAPTOPRIL 00185006110 1 ACE_INHIBITORS CAPTOPRIL 00185047101 1 ACE_INHIBITORS CAPTOPRIL 00185059101 1 ACE_INHIBITORS CAPTOPRIL 00364262801 1 ACE_INHIBITORS CAPTOPRIL 00364262901 1 ACE_INHIBITORS CAPTOPRIL 00364263001 1 ACE_INHIBITORS CAPTOPRIL 00364263101 1 ACE_INHIBITORS CAPTOPRIL 00378300701 1 ACE_INHIBITORS CAPTOPRIL 00378300710 1 ACE_INHIBITORS CAPTOPRIL 00378301201 1 ACE_INHIBITORS CAPTOPRIL 00378301210 1 ACE_INHIBITORS CAPTOPRIL 00378301701 Appendix D 5 CHC-CVD final report 110715 drug_class DRUG_GROUP GENERIC_NM NDC 1 ACE_INHIBITORS CAPTOPRIL 00378301710 1 ACE_INHIBITORS CAPTOPRIL 00378302201 1 ACE_INHIBITORS CAPTOPRIL 00677159301 1 ACE_INHIBITORS CAPTOPRIL 00781182801 1 ACE_INHIBITORS CAPTOPRIL 00781182901 1 ACE_INHIBITORS CAPTOPRIL 00781182910 1 ACE_INHIBITORS CAPTOPRIL 00781183801 1 ACE_INHIBITORS CAPTOPRIL 00904504561 1 ACE_INHIBITORS CAPTOPRIL 00904504660 1 ACE_INHIBITORS CAPTOPRIL 00904504780 1 ACE_INHIBITORS CAPTOPRIL 38245031210 1 ACE_INHIBITORS CAPTOPRIL 49884044401 1 ACE_INHIBITORS CAPTOPRIL 49884044501 1 ACE_INHIBITORS CAPTOPRIL 49884044601 1 ACE_INHIBITORS CAPTOPRIL 49884061901 1 ACE_INHIBITORS CAPTOPRIL 49884061910 1 ACE_INHIBITORS
Load more

Recommended publications
  • This Table Summarizes Changes to the HF Qxq As of 10/11/2019 Question
    Updated HFS Instructions (QxQs) This table summarizes changes to the HF QxQ as of 10/11/2019 Question in HF QxQ Description of Changes in HF QXQ General Instructions, pg. 3 Clarification added to rules for history Q29.d.10., pg. 40 Clarification made on how to record pulmonary hypertention Q29.d.14., pg. 41 Clarification made on how to record diastolic dysfunction Q42., pg. 42 Clarification made on how to record troponin I Section VII: Medication, pg. 54 Clarificaiton made on how to record medications Appendix A, pg. 61 Updated list of medications Edoxaban (ACOAG, Generic) Lixiana (ACOAG, Trade) Prexxartan (ARB, Trade) INSTRUCTIONS FOR COMPLETING HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM HFS Version C, 10/1/2015 HFA Version D, 10/1/2015 HF QxQ, 10/11/2019 Table of Contents Page General Instructions……………………………………………………………….. 2 Specific Items………………………………………………………………………. 3 Section l: Screening for Decompensation………………………………….. 5 Section ll: History of Heart Failure…………………………………………... 10 Section lll: Medical History ………………………………………………….. 13 Section lV: Physical Exam - Vital Signs…………………………………….. 24 Section V: Physical Exam - Findings……………………………………….. 26 Section Vl: Diagnostic Tests…………………………………………………. 31 Section Vll: Biochemical Analyses………………………………………….. 48 Section Vlll: Interventions…………………………………………………….. 51 Section lX: Medications………………………………………………………. 54 Section X: Complications Following Events………………………………… 59 Section Xl: Administrative……………………………………………………. 60 Appendix A: ARIC Heart Failure/Cardiac Drugs: ………………………………. 61 Alphabetical Sort Appendix B: Potential Scenarios of the Onset of Heart………………………. 73 Failure Event or Decompensation HF QxQ 10/11/2019 Page 1 of 73 General Instructions The HFAA form was initially used for all discharges selected for HF surveillance. It was replaced by the HFAB and HFSA forms and then updated June 2012 with HFAC and HFSB.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • MIRADON FPO Brand of Anisindione Tablets
    R 1 2 3 4 5 3 4 F-16099775 1898 ® MIRADON FPO brand of anisindione Tablets DESCRIPTION MIRADON Tablets contain a syn- thetic anticoagulant, anisindione, an indanedione derivative. Each tablet contains 50 mg anisin- dione. They also contain: corn starch, FD&C Red No. 3, gelatin, lactose, and hydrogenated cotton- seed oil. ACTIONS Like phenindione, to which it is re- lated chemically, anisindione exercises its thera- peutic action by reducing the prothrombin activity of the blood. INDICATIONS Anisindione is indicated for the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrilla- tion with embolization, the prophylaxis and treat- ment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. CONTRAINDICATIONS All contraindications to oral anticoagulant therapy are relative rather than absolute. Contraindications should be evaluated for each patient, giving consideration to the need for and the benefits to be achieved by anticoagu- lant therapy, the potential dangers of hemor- rhage, the expected duration of therapy, and the quality of patient monitoring and compliance. Hemorrhagic Tendencies or Blood Dyscrasias: In general, oral anticoagulants are contraindi- cated in patients who are bleeding or who have hemorrhagic blood dyscrasias or hemorrhagic tendencies (eg, hemophilia, polycythemia vera, purpura, leukemia) or a history of bleeding dia- thesis. They are contraindicated in patients with recent cerebral hemorrhage, active ulceration of the gastrointestinal tract, including ulcerative colitis, or open ulcerative, traumatic, or surgical wounds. Oral anticoagulants may be contraindi- cated in patients with recent or contemplated brain, eye, or spinal cord surgery or prostatec- tomy, and in those undergoing regional or lumbar block anesthesia or continuous tube drainage of the small intestine.
    [Show full text]
  • WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/401 (2006.01) A61P 9/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/405 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7048 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/039904 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 May 2013 (07.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/644,134 8 May 2012 (08.05.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants : STEIN, Emily A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection
    DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Committee. INSTITUTION National Heart, Lung, and Blood Inst. (DHHS/NIH), Bethesda, MD. PUB DATE 88 NOTE 64p. PUB TYPE Guides - Non-Classroom Use (055) EDRS PRICE MF01/PC03 Plus Postage. DESCRIPTORS *Cardiovascular System; Clinical Diagnosis; *Drug Therapy; *Hypertension; *Pharmacology; Physical Examinations; Physical Health; *Physical Therapy ABSTRACT The availability of an increased variety of therapeutic approaches provides the opportunitl to improve hypertension control while minimizing adverse effects that may influence cardiovascular complications and adherence to therapy. This report serves two purposes: (1) to guide practicing physicians and other health professionals in their care of hypertensive patients; and (2) to guide health professionals participating in the many community high blood pressure control programs. Contents include: (1) definition and prevalence of high blood pressure; (2) detection, confirmation and referral; (3) evaluation and diagnosis; (4) treatment--nonpharmacologic and pharmacologic therapy, and long-term maintenance of therapy; (5) considerations in individual therapy; and (6) special populations and management problems. Fifty-five references are included. (JD) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. ************************************-*********************************
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]